Tumor angiogenesis inhibitors can be broadly classified into two groups: drugs that inhibit the binding of VEGF-A and VEGFR or multikinase inhibitors that are small molecules that inhibit the kinase activity of VEGFR. This evidence concerns the gene KDR and neoplasm.